Cargando…

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells

Effective adoptive T cell therapy (ACT) comprises the killing of cancer cells through the therapeutic use of transferred T cells. One of the main ACT approaches is chimeric antigen receptor (CAR) T cell therapy. CAR T cells mediate MHC-unrestricted tumor cell killing by enabling T cells to bind targ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benmebarek, Mohamed-Reda, Karches, Clara Helke, Cadilha, Bruno Loureiro, Lesch, Stefanie, Endres, Stefan, Kobold, Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470706/ https://www.ncbi.nlm.nih.gov/pubmed/30875739 http://dx.doi.org/10.3390/ijms20061283

Ejemplares similares

Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
por: Stoiber, Stefan, et al.
Publicado: (2019)

Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job
por: Schwerdtfeger, Melanie, et al.
Publicado: (2021)

Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors
por: Cadilha, Bruno L., et al.
Publicado: (2021)

Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells
por: Darowski, Diana, et al.
Publicado: (2019)

NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development
por: Bashiri Dezfouli, Ali, et al.
Publicado: (2021)

Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer
por: Kandra, Prameela, et al.
Publicado: (2022)

Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners
por: Stock, Sophia, et al.
Publicado: (2022)

Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy
por: Lorenzini, Theo, et al.
Publicado: (2023)

Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors
por: Stock, Sophia, et al.
Publicado: (2022)

High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy
por: Rataj, Felicitas, et al.
Publicado: (2018)

Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing
por: Liao, Qibin, et al.
Publicado: (2020)

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
por: Galli, Eugenio, et al.
Publicado: (2021)

Impact of the selective A2(A)R and A2(B)R dual antagonist AB928/etrumadenant on CAR T cell function
por: Seifert, Matthias, et al.
Publicado: (2022)

Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells
por: Strohl, William R., et al.
Publicado: (2019)

Chimeric Antigen Receptor beyond CAR-T Cells
por: Qin, Vicky Mengfei, et al.
Publicado: (2021)

Humanized Chimeric Antigen Receptor (CAR) T cells
por: Kozani, Pouya Safarzadeh, et al.
Publicado: (2021)

Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins
por: Blaeschke, Franziska, et al.
Publicado: (2021)

A modular and controllable T cell therapy platform for acute myeloid leukemia
por: Benmebarek, Mohamed-Reda, et al.
Publicado: (2021)

Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma
por: Märkl, Florian, et al.
Publicado: (2023)

CAR T cell therapy in solid tumors: a short review
por: Umut, Öykü, et al.
Publicado: (2021)

Metabolic and Mitochondrial Functioning in Chimeric Antigen Receptor (CAR)—T Cells
por: Rad S. M., Ali Hosseini, et al.
Publicado: (2021)

CAR T Cells Targeting Membrane-Bound Hsp70 on Tumor Cells Mimic Hsp70-Primed NK Cells
por: Bashiri Dezfouli, Ali, et al.
Publicado: (2022)

Chimeric-Antigen-Receptor (CAR) T Cells and the Factors Influencing their Therapeutic Efficacy
por: Kravets, Victoria G, et al.
Publicado: (2017)

Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy
por: Sridhar, Praveen, et al.
Publicado: (2017)

Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting
por: Sutherland, Ashley R., et al.
Publicado: (2020)

Innovations in cancer immunotherapy: chimeric antigen receptor T-cell therapy (CAR-T)
por: Brown, Kevin, et al.
Publicado: (2021)

Targeting gastrointestinal cancers with chimeric antigen receptor (CAR)-T cell therapy
por: Staudt, Ross E, et al.
Publicado: (2022)

Special Chimeric Antigen Receptor (CAR) Modifications of T Cells: A Review
por: Miao, Lele, et al.
Publicado: (2022)

CAR‐T‐OPENIA: Chimeric antigen receptor T‐cell therapy‐associated cytopenias
por: Taneja, Alankrita, et al.
Publicado: (2021)

Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice
por: Gajra, Ajeet, et al.
Publicado: (2022)

Chimeric Antigen Receptor (CAR) Regulatory T-Cells in Solid Organ Transplantation
por: Gille, Ilse, et al.
Publicado: (2022)

Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy
por: Choi, Gyeyoung, et al.
Publicado: (2022)

Non-viral chimeric antigen receptor (CAR) T cells going viral
por: Balke-Want, H., et al.
Publicado: (2023)

Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment
por: Huynh, Duc, et al.
Publicado: (2022)

PD-1-CD28 fusion protein strengthens mesothelin-specific TRuC T cells in preclinical solid tumor models
por: Lesch, Stefanie, et al.
Publicado: (2022)

Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T
por: Yoon, Dok Hyun, et al.
Publicado: (2018)

The Effects of Chimeric Antigen Receptor (CAR) Hinge Domain Post-Translational Modifications on CAR-T Cell Activity
por: Hirobe, Sachiko, et al.
Publicado: (2022)

convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting
por: Landgraf, Kyle E., et al.
Publicado: (2020)

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
por: Grada, Zakaria, et al.
Publicado: (2013)

Chimeric antigen receptor (CAR)+ T cell selection method affects transgene efficacy
por: Rushworth, David, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_i4knv5cq1podv3csgofr6fv4ch